Mitigating Toxicity & Revolutionizing Muscle Targeting
challenges and effectively translate their programs into the clinic.
Highlighting AAV and gene editing challenges for Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease, X-Linked Myotubular Myopathy and other muscular disorders, this industry-focused 4-day event will cover:
- Overcoming immunogenicity challenges and mitigate toxicity with high doses
- Optimizing vector and promoter choice and design for more efficient delivery tomuscle targets
- Defining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets
Join over 150 fellow industry experts to learn, share and benchmark yourselves against your competitors, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle.
To know more visit: https://ter.li/tbbaua